History and Evolution of Clinical Research Regulation in India – Recent Reforms and Current Landscape

This article is the second part of a two-part series on the history of clinical research regulation in India. Part One examined the foundational period from the colonial era through the emergence of structured clinical trial governance, including the Drugs and Cosmetics Act 1940, the formation of CDSCO, the Indian GCP Guidelines of 2001, and the Revised Schedule Y of 2005. This article picks up at the point where rapid growth in global trial activity began exposing the limits of that foundational framework.

---

Introduction

By the mid-2000s, India had positioned itself as one of the world's most attractive destinations for international clinical research. The revised Schedule Y (2005) had aligned India's clinical trial requirements more closely with international standards. The TRIPS-compliant product patent regime (2005) had demonstrated India's commitment to intellectual property frameworks that pharmaceutical companies required. A large, treatment-naive, genetically diverse patient population and a growing base of GCP-trained investigators made the scientific case for India compelling. 

What followed was a period of rapid growth — and then a crisis that nearly dismantled the industry entirely.

The period from 2008 to 2019 is the most consequential decade in the history of Indian clinical research regulation. It encompasses a collapse in public and judicial confidence, a period of severe regulatory restriction that drove sponsors away from India, and ultimately a comprehensive legislative overhaul that produced the most sophisticated clinical trial regulatory framework India has ever had. Understanding this arc — what went wrong, why, and how the system responded — is essential context for anyone operating in India's clinical research environment today.

Rapid Growth and the Emergence of Systemic Concerns (2008–2011)

The volume of clinical trials conducted in India grew dramatically in the years following Schedule Y's revision. Between 2005 and 2011, the number of new clinical trial applications to CDSCO increased several-fold. Global pharmaceutical companies, attracted by the scientific, logistical, and cost advantages that India offered, increasingly included Indian sites in multinational trial programs.

This growth exposed structural vulnerabilities in India's regulatory and ethical oversight infrastructure that had not been apparent at lower trial volumes:

Informed Consent Failures

Multiple investigations — by parliamentary committees, journalists, and civil society organizations — documented serious deficiencies in informed consent processes across clinical trial sites. Participants, often from economically vulnerable populations with limited health literacy, were found to have signed consent forms without adequate understanding of the nature of their participation, the experimental status of the treatment, or the risks involved. In some documented cases, consent had been obtained in languages participants did not speak, or by individuals without appropriate authority or training.

The informed consent failures were not isolated incidents — they reflected a systemic absence of the patient education, language-appropriate materials, and independent oversight that genuine informed consent requires.

The Compensation Crisis

The question of compensation for trial-related injury became the most politically visible regulatory issue of this period. India had no clearly defined legal framework specifying when compensation was owed to trial participants, how injury relatedness was to be determined, or what quantum of compensation was appropriate. Reports of participant deaths and serious injuries — some in trials that had been improperly designed or monitored — with little or no compensation provided to affected families generated intense public and media attention.

A parliamentary standing committee investigation of trial-related deaths between 2005 and 2012 documented hundreds of deaths in clinical trials, though the causal relationship between trial participation and death was contested in many cases. The absence of a transparent, standardized determination process — and the perception that sponsors and investigators faced no meaningful accountability — fundamentally undermined public trust.

Oversight Gaps at the Investigator and Site Level

The rapid expansion of India's trial portfolio had outpaced the capacity of CDSCO and Ethics Committees to provide adequate oversight. Key structural gaps included:

Investigator overload: Some principal investigators were simultaneously listed on 10, 20, or more active clinical trials — a volume incompatible with the active scientific and safety oversight that GCP requires of principal investigators. Regulatory systems had no mechanism to detect or limit this concentration.

Ethics Committee quality variation: Hundreds of institutional Ethics Committees operated across India with no registration requirement, no minimum composition standards, and no external accountability. The quality of ethical review varied enormously — from genuinely rigorous independent review to perfunctory approval processes that provided no meaningful participant protection.

Monitoring deficits: CDSCO's capacity for clinical trial site inspections was limited relative to the volume of active trials. The combination of an under-resourced regulatory inspectorate and Ethics Committees of variable quality meant that serious protocol violations and informed consent failures could persist undetected.

Judicial Intervention and the Reform Crisis (2011–2013)

The accumulation of documented failures triggered a response from India's judiciary that would reshape the regulatory landscape more dramatically than any planned reform.

In 2012, the Supreme Court of India took up public interest litigation challenging the adequacy of clinical trial oversight. The Court's intervention was not merely advisory — it resulted in direct orders to CDSCO and the Ministry of Health that fundamentally altered the regulatory environment:

• Suspension of new clinical trial approvals: CDSCO effectively halted new clinical trial approvals for a period as the Court examined regulatory adequacy. International sponsors who had planned to initiate trials in India found the pathway closed.
• Mandatory audiovisual documentation of informed consent: The Court ordered that informed consent processes be audiovisually recorded to create a verifiable record of participant understanding and voluntariness — a requirement unprecedented in major international regulatory jurisdictions.
• Limitations on investigator trial participation: Restrictions were placed on the number of active trials any single investigator could conduct simultaneously, addressing the overload problem that had been documented.
• Compensation determination framework: The Court directed development of a structured framework for determining compensation in trial-related injury and death cases, replacing the ad hoc case-by-case approach that had generated such controversy.

The period from 2012 to 2015 saw a dramatic contraction in India's clinical trial activity. The number of new IND applications approved by CDSCO dropped from 263 in 2012 to 17 in 2014 — a decline of more than 90%. International sponsors redirected development programs to other Asian markets. India's position as a global clinical research destination had, within the space of three years, been severely damaged.

Regulatory Reconstruction (2013–2018)

The period of severe restriction was followed by a more measured process of regulatory reconstruction — building the governance infrastructure that should have existed before the crisis, rather than simply reopening the trial pipeline to previous volumes.

Ethics Committee Registration and Standardization

The mandatory registration of Ethics Committees with CDSCO was one of the most consequential structural reforms of this period. Registration requirements established minimum standards for EC composition — requiring specified proportions of medical, scientific, legal, and lay members — operational procedures, member training, conflict of interest management, and record-keeping. ECs that could not meet these standards could not review clinical trials.

This reform did not create perfect Ethics Committees overnight. But it created a baseline of accountability and a mechanism for regulatory oversight of the review process itself — neither of which had previously existed.

The Compensation Framework

Detailed regulatory guidance established a structured methodology for determining compensation in cases of trial-related injury or death. The framework specified:

• Causality assessment methodology: A structured process for determining the degree to which a participant's injury or death was attributable to trial participation, the investigational product, or underlying disease
• Compensation quantum formula: A formula incorporating the participant's age, income, nature and severity of injury, and assessed degree of trial relatedness to determine compensation amounts
• Mandatory medical management: Sponsors were required to provide medical treatment for trial-related injuries, independent of compensation payments
• Timelines for determination: Defined timeframes for completing causality assessments and delivering compensation decisions

This framework — however imperfect in its initial form — transformed compensation from an ad hoc negotiation into a defined regulatory obligation with specified procedures and timelines.

Restructuring of CDSCO's Expert Review Process

The regulatory review architecture underwent significant structural reform:

New Drug Advisory Committees (NDACs) — the expert bodies that had previously reviewed clinical trial applications — were replaced by Subject Expert Committees (SECs), which were constituted with clearer mandates, defined membership criteria, and more transparent operating procedures.

A Technical Review Committee (TRC) was established as an additional layer of expert review for complex applications, providing a further check on regulatory decisions and reducing the concentration of decision-making authority.

These structural reforms increased the rigor and defensibility of regulatory decisions — at the cost of further slowing an already constrained approval pipeline during the transition period.

Rebuilding Approval Volume: A Gradual Recovery

The recovery in clinical trial approvals through 2015–2018 was gradual and deliberate. CDSCO prioritized quality of oversight over volume of approvals — a reversal of the implicit priorities that had characterized the rapid growth period. The number of approved trials increased year by year but did not return to pre-crisis volumes until the fundamental framework reform of 2019 provided a sustainable regulatory architecture.

The New Drugs and Clinical Trials Rules, 2019: A Comprehensive Legislative Overhaul

The New Drugs and Clinical Trials (NDCT) Rules, 2019 — enacted under the Drugs and Cosmetics Act, 1940, and replacing the legacy Schedule Y framework entirely — represent the most comprehensive reform of India's clinical trial regulatory framework since the Drugs and Cosmetics Act itself.

The NDCT Rules did not simply update existing provisions — they created a new regulatory architecture designed to address the failures of the pre-crisis period while positioning India for participation in modern, technology-enabled, globally integrated clinical research.

Defined Regulatory Timelines

One of the most significant practical improvements of the NDCT Rules is the establishment of legally defined timelines for regulatory decisions:

• 30 working days for clinical trial approval of new drugs already approved in ICH-member countries seeking to run simultaneous global trials in India
• 30 working days for other new drug clinical trial applications following SEC review
• Deemed approval provisions: If CDSCO fails to communicate a decision within the specified timeline, the application is deemed approved under defined circumstances — a provision with no precedent in Indian pharmaceutical regulation

These timelines transformed India's regulatory environment from one characterized by unpredictable multi-month or multi-year waits into one where sponsors could plan development programs with meaningful timeline certainty.

Simultaneous Global Trial Participation

The NDCT Rules explicitly permit simultaneous Phase I, II, and III trials — Indian sites can enroll patients at the same time as sites in the US, EU, Japan, and other ICH markets. This ended the historical practice of requiring India-specific trials to wait for global results — a requirement that had positioned India as a second-tier destination for international development programs and denied Indian patients early access to investigational therapies.

The scientific and ethical significance of this change extends beyond operational convenience. Simultaneous participation means that Indian patients contribute to the evidence base that supports global regulatory decisions — rather than being excluded from the research that generates treatments they will eventually use.

Strengthened Compensation and Medical Management

The compensation framework — developed in response to the judicial crisis — was codified and refined in the NDCT Rules, with clear provisions for:

• Mandatory medical management of trial-related injuries at the sponsor's expense
• Defined causality assessment procedures and timelines
• Compensation formula incorporating participant demographics, injury severity, and relatedness determination
• Post-trial access provisions for participants who benefit from investigational products that do not receive marketing authorization

Simplified Academic and Investigator-Initiated Trials

Recognizing that the regulatory burden of the post-crisis reform period had disproportionately affected non-commercial research conducted by Indian academic investigators, the NDCT Rules established a simplified regulatory pathway for academic clinical trials — reducing documentation requirements, fees, and approval timelines for non-commercial research conducted without industry sponsorship.

This provision acknowledged that India's domestic biomedical research capacity depends on sustainable pathways for investigator-initiated research, not only industry-sponsored multinational trials.

Orphan Drugs and Accelerated Approval Pathways

The NDCT Rules formalized accelerated approval mechanisms for drugs intended to treat serious or life-threatening conditions with unmet medical need — including orphan drugs for rare diseases. These provisions include:

• Priority review designation with shorter regulatory timelines
• Conditional approval based on surrogate or intermediate endpoints with post-approval confirmatory study requirements
• Waivers of local clinical trial requirements for drugs with established efficacy in similar populations internationally

These pathways are particularly significant for India's rare disease patient community — historically among the most under-served by both clinical research and access to approved therapies.

Digital Transformation and Regulatory Transparency

The NDCT Rules were accompanied by a broader digital modernization of CDSCO's operational infrastructure:

The SUGAM Portal

The SUGAM online regulatory submission portal replaced paper-based application processes for clinical trial applications, import licenses, marketing authorization applications, and other regulatory filings. SUGAM provides:

• Standardized electronic application forms
• Online document upload and version control
• Electronic fee payment
• Application status tracking accessible to sponsors
• Automated acknowledgment and communication workflows

The transition to SUGAM has improved submission consistency, reduced administrative processing time, and — critically — created a transparent, auditable regulatory workflow that reduces opportunities for the informal processes that had characterized the pre-reform era.

Mandatory CTRI Registration

Prospective registration of all clinical trials with the Clinical Trials Registry – India (CTRI) — operated by ICMR — became a legally enforceable requirement under the NDCT Rules. CTRI registration before first patient enrollment ensures:

• Public transparency about ongoing trial activity in India
• Accountability for trial conduct against registered protocols
• Contribution to the global clinical trial registry ecosystem (CTRI data feeds into the WHO's International Clinical Trials Registry Platform)
• A mechanism for identifying discrepancies between registered protocols and actual trial conduct during regulatory inspections

Online Regulatory Tracking

CDSCO's commitment to online tracking of regulatory decisions — with application status accessible to sponsors through SUGAM — represented a significant transparency improvement over the pre-reform era, when regulatory decision timelines were opaque and sponsors had limited visibility into where their applications stood in the review process.

India's Regulatory Alignment With International Standards

A defining characteristic of India's post-2019 regulatory framework is its systematic alignment with international regulatory norms — an alignment that enables India to participate as a peer in global development programs rather than as an adjunct market requiring special accommodation.

ICH E6(R2) GCP alignment: India's GCP requirements are aligned with the ICH E6(R2) Good Clinical Practice standard — the international benchmark against which regulatory agencies in the US, EU, Japan, and other ICH markets evaluate clinical trial conduct. This alignment means that data generated in Indian trials is credible to international regulatory agencies without requiring additional validation.

ICH guideline adoption: India has adopted or aligned with the principal ICH guidelines governing clinical development — including ICH M3(R2) on non-clinical safety studies, ICH E8(R1) on general considerations for clinical studies, and the ICH E2 series on pharmacovigilance — creating a consistent scientific framework across the development lifecycle.

Global pharmacovigilance integration: India's PvPI pharmacovigilance network is integrated with the WHO Uppsala Monitoring Centre's global signal detection infrastructure — meaning Indian safety data contributes to and benefits from global pharmacovigilance intelligence.

Mutual recognition discussions: India has engaged in discussions with several regulatory authorities about data sharing and mutual recognition frameworks that would further reduce the duplication of regulatory effort across jurisdictions — a significant efficiency gain for sponsors running global development programs.

The Current Landscape: An Ecosystem Rebuilt

India's clinical research ecosystem in 2025 looks fundamentally different from the one that existed before the crisis — and the differences reflect deliberate regulatory choices rather than simply the passage of time.

Regulatory predictability: The defined timelines and deemed approval provisions of the NDCT Rules have transformed India from a jurisdiction characterized by unpredictable regulatory timelines into one where sponsors can build realistic development plans. This predictability is arguably the single most important factor in a sponsor's market entry decision.

Ethical governance infrastructure: The registered EC network — with defined composition, operating procedure, and accountability requirements — provides a level of ethical oversight quality consistency that was entirely absent before the crisis. India now has more than 250 CDSCO-registered Ethics Committees operating under standardized minimum standards.

Participant protection codification: Compensation frameworks, informed consent requirements (including the audiovisual documentation mandate), and post-trial access provisions together constitute a participant protection framework that — in its codified form — is more comprehensive than existed at any prior point in Indian regulatory history.

Growing CDSCO inspection capacity: CDSCO's GCP inspection program has expanded, with increasing numbers of clinical trial site inspections conducted annually. The existence of an active inspection program — with consequences for non-compliance — provides a deterrent function that was largely absent in the pre-crisis period.

Investigator network quality: The combination of EC registration requirements, investigator limitation provisions, and GCP training expectations has contributed to a gradual quality improvement in India's active investigator network — though training consistency and infrastructure quality variation across sites remains a legitimate concern for sponsors.

Unresolved Challenges and the Road Ahead

Honest assessment of India's regulatory evolution requires acknowledging what remains unresolved alongside what has been achieved:

SUGAM portal operational friction: While SUGAM has improved transparency and consistency, technical issues — including portal downtime, document format requirements, and electronic payment failures — continue to create operational delays for sponsors during the submission process.

EC quality variation: While registered ECs now operate under minimum standards, the gap between the best and least capable ECs remains significant. Review timelines, documentation quality, and scientific rigor continue to vary substantially — and sponsors cannot always predict which EC characteristics will affect their specific study.

Decentralized trial framework: India lacks a comprehensive regulatory guidance document for decentralized clinical trial elements — remote visits, home health nurses, ePRO, wearables — equivalent to the FDA's 2023 DCT guidance or EMA's corresponding framework. CDSCO has signaled awareness of this gap, but formal guidance is pending.

Real-world evidence framework: A structured regulatory pathway for RWE submissions to support label expansions, post-marketing requirements, or comparative effectiveness claims has not yet been formalized by CDSCO — though the data infrastructure required (ABDM digital health records, PvPI pharmacovigilance data) is developing.

Rare disease ecosystem: Despite the NDCT Rules' orphan drug provisions, India's rare disease patient community continues to face significant delays in accessing approved therapies. The gap between orphan drug approval provisions and actual patient access — driven by pricing, reimbursement, and supply chain factors beyond the regulatory framework — remains a significant unmet challenge.

Conclusion

The history of clinical research regulation in India between 2008 and the present is a story of crisis, consequence, and reconstruction — played out against the backdrop of a country navigating the tension between becoming a global scientific partner and protecting its most vulnerable citizens from exploitation.

The crisis of 2011–2015 was painful and costly — for sponsors who lost access to a valuable market, for investigators whose professional reputations were damaged by association, and most acutely for patients whose access to investigational therapies was delayed by years. But the reforms it catalyzed — the NDCT Rules, EC registration, the compensation framework, SUGAM, CTRI — produced a regulatory architecture that is genuinely more protective, more transparent, and more globally integrated than anything that existed before.

India's regulatory journey is not complete. The frontiers of decentralized trials, real-world evidence, artificial intelligence in clinical research, and advanced therapy medicinal products will test the adaptability of any regulatory framework. What the post-2019 environment demonstrates is that India's regulatory institutions have the capacity to learn from failure, respond to external pressure, and build frameworks commensurate with the complexity of modern clinical research.

That capacity — more than any specific regulatory provision — is the most important asset India's clinical research ecosystem possesses.

Genelife Clinical Research Pvt. Ltd. has operated throughout the evolution of India's clinical research regulatory landscape, building regulatory expertise and operational capabilities aligned with each phase of framework development. Visit www.genelifecr.com to learn about our regulatory services.

Related Insights

1. CDSCO Approval Process for Clinical Trials in India: Complete Guide
2. History of Clinical Research Regulation in India
3. What is a CRO? Role of Clinical Research Organizations in India
4. Clinical Trial Process in India: Step-by-Step Guide

Patient Recruitment Challenges in Clinical Trials and How to Overcome Them

Smarter Patient Recruitment Through Disease Surveillance

Introduction

Approximately 80% of clinical trials fail to meet their original enrollment timelines. The median delay attributable to recruitment shortfalls is six months — but for complex trials in competitive therapeutic areas, delays of one to two years are not uncommon. The downstream consequences compound rapidly: every month of delay in a pivotal trial can cost a sponsor between $600,000 and $8 million in direct expenses and lost market opportunity, depending on the indication and development stage.

Patient recruitment is consistently ranked as the single greatest operational challenge in clinical research — ahead of regulatory complexity, data management, and site performance. Yet it receives proportionally less strategic investment than these other domains. Most recruitment failures are not random — they are the predictable result of avoidable decisions made months before the first patient is screened: protocols designed without feasibility input, sites selected on convenience rather than patient access, and enrollment projections built on optimism rather than data.

This article examines the structural causes of recruitment failure, the evidence-based strategies that address them, and a disease surveillance methodology that is transforming how sites are identified and patient populations are mapped in India's clinical research landscape.

Why Patient Recruitment Defines Trial Success

The consequences of recruitment failure extend well beyond schedule delays. Consider the compounding effects:

Scientific integrity: Trials that fail to reach their target sample size are statistically underpowered. Underpowered studies produce inconclusive results — wasting resources, delaying regulatory decisions, and potentially exposing future patients to treatments whose benefit-risk profile remains unclear.

Regulatory credibility: Enrollment shortfalls often trigger protocol amendments — adding sites, relaxing eligibility criteria, or extending enrollment windows. Each substantial amendment requires regulatory notification, EC approval, and updated consent procedures. Multiple amendments signal operational instability to regulators and can delay review timelines.

Financial impact: The majority of clinical trial costs are time-dependent — site management fees, investigator payments, CRO overhead, and investigational product supply all continue regardless of whether patients are enrolling. A trial running at 50% of projected enrollment rate doubles the duration of these fixed costs.

Retention cascades from recruitment: Trials that struggle to recruit frequently make compensatory decisions — accepting borderline-eligible patients, enrolling at poorly prepared sites, or accelerating consent processes — that increase dropout rates during the study. Poor recruitment and poor retention are often manifestations of the same underlying problems.

The Structural Causes of Recruitment Failure

Understanding why trials fail to recruit requires looking beyond surface-level explanations. The root causes are almost always structural — embedded in design, planning, and site selection decisions made before the trial begins.

1. Protocol Design Misaligned With Clinical Reality

The most common and most consequential recruitment problem is a protocol that the target patient population cannot practically fulfill. This takes several forms:

Overly restrictive eligibility criteria: Every inclusion and exclusion criterion added to a protocol reduces the eligible population. Individual criteria are added for sound scientific or safety reasons — but their cumulative effect is frequently underestimated. A study of oncology trials found that the average protocol has 31 eligibility criteria, and that relaxing a subset of the most restrictive criteria could increase eligible populations by 40 to 60%.

Excessive visit burden: Protocols requiring frequent site visits, lengthy procedures, or complex patient preparation create barriers that lead patients to decline participation or withdraw after enrollment. Visit burden disproportionately excludes working adults, caregivers, patients in rural areas, and those with mobility limitations — the same populations often underrepresented in trial data.

Unrealistic washout periods: Extended washout periods that require patients to discontinue effective treatments before screening are a major barrier, particularly in therapeutic areas where patients have few alternatives to current therapies.

2. Site Selection Based on Relationships Rather Than Data

The traditional site selection process — driven by existing investigator relationships, geographic convenience, and self-reported feasibility questionnaire responses — is a systematic generator of recruitment underperformance. The problem is that investigator enthusiasm during feasibility assessment does not reliably predict actual enrollment capacity.

Sites are frequently selected based on:

• Prior working relationships with the CRO or sponsor
• Geographic proximity to the sponsor or CRO office
• Investigator interest expressed in feasibility surveys

These factors have weak correlation with actual patient availability in the specific indication being studied. The result is a site network populated with willing but under-resourced sites, while high-potential sites in less obvious geographies are overlooked.

3. Competitive Trial Burden

In high-priority therapeutic areas — oncology, cardiovascular disease, diabetes, rare diseases — a single institution may be running 20 to 50 concurrent trials competing for the same patient population. Investigators and research coordinators are finite resources, and sites that appear highly capable in isolation may be unable to deliver expected enrollment when their total trial portfolio is considered.

Competitive trial burden is one of the most underanalyzed dimensions of site feasibility — and one of the most predictive of site underperformance.

4. Patient Awareness and Access Barriers

Clinical trial participation rates remain low across most patient populations, driven by a combination of awareness gaps, access barriers, and trust deficits:

Awareness: Studies consistently find that the majority of cancer patients — and even larger proportions of patients with other conditions — are unaware that clinical trials relevant to their condition exist. Physician referral remains the primary pathway to trial participation, and many physicians either do not discuss trial options or lack current knowledge of available studies.

Access: Geographic barriers — the distance between where patients live and where trials are conducted — remain significant, particularly in India's vast geographic and demographic landscape. Trials concentrated in metropolitan academic centers exclude large rural patient populations who may represent the most medically underserved and treatment-naive participants.

Trust: Historical exploitation of vulnerable populations in research has created lasting trust deficits — particularly among lower socioeconomic groups and communities with limited healthcare literacy. Rebuilding trust requires sustained community engagement, not enrollment-period outreach campaigns.

5. Retention Failures

Enrollment is not the endpoint of the recruitment challenge — retention is. Patients who withdraw before completing the protocol generate incomplete data, reduce effective sample size, and in some trial designs introduce bias that cannot be fully corrected statistically.

Dropout rates in clinical trials average 30% across therapeutic areas, with significantly higher rates in trials with long duration, high visit frequency, or significant symptom burden from the investigational product. Retention is systematically under-planned — treated as a problem to address if it arises, rather than a design challenge to prevent.

Evidence-Based Strategies for Improving Recruitment

Protocol Feasibility Review Before Finalization

The most impactful intervention in recruitment planning is engaging clinical investigators in protocol feasibility review before the protocol is finalized — not after. This requires sponsors and CROs to share draft protocols with practicing clinicians who treat the target patient population, soliciting honest assessment of:

• Whether the eligibility criteria accurately reflect the patients they see
• Which specific criteria would exclude the majority of otherwise suitable patients
• Whether the visit schedule and procedures are compatible with their patients' lives
• What concomitant medication and prior treatment patterns look like in their practice

Modifications made at this stage cost almost nothing. Modifications made after regulatory submission — requiring protocol amendments, EC re-approvals, and CTRI updates — cost months.

Data-Driven Site Selection

Replacing relationship-based site selection with data-driven feasibility assessment is the highest-leverage operational improvement most sponsors and CROs can make in recruitment performance. Data-driven site selection uses:

• Disease prevalence and incidence data at the local, regional, and site level to estimate the actual patient pool available in the specific indication
• Prescription database analysis to identify sites where investigators are actively treating patients with the standard of care that defines the target population
• Prior trial performance data — enrollment rates, protocol deviation frequency, data quality metrics — from comparable studies at candidate sites
• Competitive trial mapping to identify sites whose current trial portfolios create enrollment conflicts
• Patient geography analysis to identify sites accessible to the patient populations with the highest disease burden

Disease Surveillance Research: Genelife's Approach

At Genelife Clinical Research, we have developed a structured Disease Surveillance Research (DSR) methodology that applies epidemiological surveillance techniques to the clinical trial site selection and patient recruitment challenge.

Disease surveillance — traditionally used by public health agencies to track disease prevalence, incidence trends, and geographic distribution — provides a systematic, data-grounded framework for understanding where patients are, who is treating them, and which sites have the genuine patient access that enrollment projections require.

How Genelife's DSR Methodology Works

Rather than relying on investigator self-reported feasibility questionnaires — which are subject to optimism bias and incomplete information — the DSR methodology conducts structured, systematic surveys across therapeutic areas and geographies to build a ground-truth database of investigator capacity and patient availability.

Scope of the program: Genelife has conducted structured DSR surveys across India, covering major therapeutic areas including cardiology, oncology, dermatology, endocrinology, infectious diseases, neurology, and respiratory medicine — across metropolitan, Tier-2, and Tier-3 cities.

Scale of evaluation: More than 800 investigators across different regions of India have been evaluated through this program, assessing:

• Actual patient volumes in the specific indication — not general practice volumes
• Current clinical research experience and GCP training status
• Site infrastructure relevant to the study requirements
• Current trial portfolio and competitive burden
• Investigator and institution interest in clinical research participation

Geographic intelligence: The DSR program maps disease distribution and investigator capacity across India's regions — identifying high-potential sites in less saturated geographies that traditional site selection processes systematically overlook. Tier-2 and Tier-3 cities frequently offer substantial patient pools with minimal competitive trial burden — a combination that metropolitan academic centers, despite their research experience, often cannot match.

What DSR Enables

More accurate enrollment projections: Site-level enrollment estimates based on actual patient availability data — not investigator enthusiasm — produce projections that more reliably predict trial performance.

Discovery of high-potential sites: The DSR database consistently surfaces sites that would not appear on a conventional site list — experienced investigators in less prominent institutions with genuine patient access in the indication of interest.

Competitive positioning: By mapping the trial portfolios of candidate sites, DSR identifies sites where the study will have preferred investigator attention rather than competing with 15 other active trials.

Faster site activation: Sites identified through DSR enter the activation process with pre-assessed infrastructure, pre-qualified investigators, and existing institutional awareness of the research program — reducing activation timelines relative to sites approached cold.

Development of new research sites: Beyond identifying established research sites, DSR identifies clinicians with high patient volumes and research interest who have not previously participated in sponsored trials — expanding India's active investigator network in a structured, quality-assured way.

Patient-Centric Trial Design

Beyond site selection, making trials genuinely accessible to patients requires deliberate design choices:

Decentralized trial elements: Remote screening visits, home health nurse visits for sample collection, local laboratory options, and electronic patient-reported outcomes (ePRO) reduce the geographic and logistical barriers that prevent many eligible patients from participating. The FDA's 2023 DCT guidance and CDSCO's evolving position on decentralized elements provide the regulatory framework for implementing these approaches.

Regional language materials: In India's multilingual landscape, informed consent documents, patient diaries, and study communication materials available only in English exclude large segments of the eligible population. Validated translations into relevant regional languages are a prerequisite for genuine patient access — not an optional enhancement.

Simplified consent processes: Multimedia consent tools — video explanations, illustrated summaries, interactive digital platforms — consistently improve participant comprehension compared to text-only documents, particularly in populations with variable health literacy.

Flexible visit scheduling: Offering evening and weekend visit options, minimizing fasting requirements where scientifically acceptable, and coordinating multiple study procedures within single visits reduces the time burden on working participants.

Digital and Community Outreach

Physician referral networks: Since physician recommendation remains the dominant pathway to trial participation, systematic engagement of referring physicians — beyond the investigator's immediate clinical network — can substantially expand the patient pipeline. This includes primary care physicians, community specialists, and disease-specific patient advocacy organizations.

Digital patient identification: Social media platforms, disease-specific online communities, and healthcare provider platforms enable targeted outreach to patients who may be actively seeking treatment options. Digital recruitment must comply with applicable advertising regulations, EC approval requirements, and data privacy obligations — including India's DPDPA 2023.

Patient advocacy organization partnerships: Collaborations with patient advocacy groups provide access to engaged patient communities, enhance trial credibility, and facilitate participant education and retention — particularly valuable in rare disease programs where patient communities are small and well-connected.

Patient Retention: The Second Half of the Recruitment Equation

Recruitment strategies that do not address retention solve only half the problem. Retention planning must begin at protocol design — not after dropout rates signal a crisis.

Pre-enrollment retention assessment: Before finalizing the protocol, honestly evaluate the expected dropout risk: How long is the trial? How burdensome are the visits and procedures? What adverse effects are anticipated, and how will they affect willingness to continue? What competing treatments will become available during the trial period?

Proactive participant communication: Regular, meaningful communication with enrolled participants — beyond protocol-required contact points — maintains engagement and signals that the research team values the participant's contribution. This includes study progress updates, acknowledgment of participant effort, and responsive handling of participant concerns.

Reimbursement and support: Transparent, fair reimbursement of trial-related expenses — travel, accommodation, time — removes financial barriers to continued participation. Logistical support — transport coordination, childcare assistance, appointment reminders — reduces the practical friction that drives dropout in long-duration trials.

Early identification of at-risk participants: Research coordinators trained to identify participants showing signs of disengagement — missed appointments, delayed questionnaire completion, reduced contact responsiveness — can intervene before withdrawal becomes inevitable.

Patient Recruitment in India: Structural Advantages and Specific Considerations

India's clinical trial landscape offers genuine structural advantages for patient recruitment — but realizing those advantages requires understanding the specific operational context.

Disease burden: India carries a substantial proportion of the global burden of non-communicable diseases — including 77 million people with diabetes, the largest TB burden of any country, and rapidly growing cardiovascular and oncology caseloads. This disease prevalence translates into large, treatment-accessible patient populations in therapeutic areas of high global development interest.

Treatment-naive populations: In some therapeutic areas, Indian patients — particularly those outside major metropolitan centers — are more likely to be treatment-naive or on minimal prior therapy than Western counterparts. This can be a significant advantage in trials where extensive prior treatment history complicates eligibility or confounds endpoints.

Investigator network depth: India has a large and growing base of GCP-trained investigators across medical specialties — including many who have completed international GCP training and have prior experience in sponsored trials. The Genelife DSR program has documented this network with a granularity that conventional feasibility processes cannot match.

Operational considerations: Effective recruitment in India requires sensitivity to regional language diversity, varying levels of health literacy across the patient population, differences in healthcare-seeking behavior between urban and rural populations, and the practical logistics of patient travel in a geographically vast country. These are not insurmountable challenges — but they are challenges that require specific operational planning, not generic global protocols applied without adaptation.

Learn more about our Patient Recruitment & Retention Services

Conclusion

Patient recruitment failure is not inevitable — it is predictable, and in large part preventable. The trials that meet enrollment timelines reliably share common characteristics: protocols designed with genuine feasibility input, sites selected on data rather than relationships, patient-centric design choices that reduce participation barriers, and retention planning embedded from the start rather than improvised in response to dropout signals.

The Disease Surveillance Research methodology represents a meaningful advance in how site selection and patient population mapping can be conducted in India — replacing the systematic optimism of traditional feasibility processes with ground-truth intelligence about where patients are and who is treating them. Combined with protocol optimization, patient-centric design, and systematic retention planning, it provides a framework for clinical trial recruitment that is both faster and more reliable.

In a development environment where time is measured in billions of dollars and trial failure is measured in patients who wait longer for effective treatments, smarter recruitment is not a competitive advantage — it is an ethical imperative.

Genelife Clinical Research Pvt. Ltd. operates a structured Disease Surveillance Research program covering 800+ investigators across India's therapeutic areas and geographies. To learn how DSR can improve enrollment performance on your clinical program, visit www.genelifecr.com

Related Insights

Genelife Perspective of Best Practices in Study Management

Phases of Clinical Trials Explained: Phase I–IV in Drug Development

Significance of Disease Surveillance Report (DSR) in Patient recruitment

Learn more about our clinical research services for end-to-end clinical trial support. 

Real World Evidence (RWE) in Clinical Research: Importance and Applications

In 2016, the US Congress passed the 21st Century Cures Act — landmark legislation that directed the FDA to develop a framework for using real-world evidence to support regulatory decisions about approved drugs, including new indications and post-approval study requirements. Three years later, the FDA published its RWE Framework, formally acknowledging that evidence generated outside traditional randomized controlled trials could, under the right conditions, inform regulatory decisions that affect millions of patients.

This was not a minor policy adjustment. It represented a fundamental rethinking of where valid clinical evidence comes from — and opened a new chapter in the relationship between clinical research, healthcare data, and regulatory science.

Real-world evidence is not new. Clinicians, epidemiologists, and health economists have analyzed observational data for decades. What is new is the scale at which healthcare data is now generated and digitized, the analytical sophistication with which it can be interrogated, and the growing regulatory acceptance of evidence derived from it. Together, these forces are reshaping how drugs are developed, evaluated, and monitored throughout their lifecycle.

What is Real-World Evidence — and What is Real-World Data?

Understanding RWE requires distinguishing two related but distinct concepts:

Real-World Data (RWD) refers to data relating to patient health status and healthcare delivery collected outside the context of conventional randomized controlled trials. RWD is generated continuously through routine clinical care — it is the data exhaust of healthcare systems.

Real-World Evidence (RWE) is the clinical evidence derived from analysis of RWD. RWD is the raw material; RWE is the structured, analyzed knowledge produced from it. The quality of RWE depends entirely on the quality and appropriateness of both the underlying data and the analytical methods applied to it.

This distinction matters because RWD in its raw form is rarely fit for research purposes. Electronic health records are designed for clinical documentation, not scientific study. Insurance claims are optimized for billing, not outcomes measurement. Converting RWD into credible RWE requires deliberate study design, rigorous data validation, and analytically sound methods — the same intellectual discipline applied to conventional clinical trials, adapted for observational settings.

Primary Sources of Real-World Data

Electronic Health Records (EHRs): Longitudinal patient data captured through routine clinical care — diagnoses, procedures, laboratory values, prescriptions, vital signs, clinical notes. EHR data offers breadth and longitudinal depth but is often incomplete, inconsistently coded, and structured for clinical rather than research purposes.

Administrative Claims and Insurance Databases: Data generated by healthcare billing systems — diagnosis codes (ICD), procedure codes (CPT, OPCS), drug dispensing records, and healthcare utilization patterns. Claims data covers large populations with consistent structure but lacks clinical granularity — laboratory values, disease severity measures, and patient-reported outcomes are typically absent.

Patient Registries: Organized systems that collect standardized data on patients with a defined disease, condition, or exposure. Disease registries (oncology, rare diseases, cardiovascular) can provide deep clinical phenotyping not available in administrative data, and can be designed prospectively with specific research questions in mind.

Wearables and Digital Health Technologies: Continuous physiological monitoring through consumer and medical-grade wearables — heart rate, activity, sleep, continuous glucose monitoring, electrocardiography — generates granular longitudinal data on patient health outside clinical settings. This data type is rapidly growing in volume and regulatory relevance.

Patient-Reported Outcomes (PROs): Directly elicited patient assessments of symptoms, function, quality of life, and treatment experience — collected through validated instruments, electronic diaries, and mobile applications. PROs capture dimensions of disease burden and treatment impact that clinician-reported data misses.

Social Determinants and Environmental Data: Socioeconomic status, housing, nutrition, environmental exposures, and geographic factors that profoundly influence health outcomes but are rarely captured in clinical trial datasets. Linkage of clinical data to social determinants databases is an emerging frontier in RWE methodology.

Post-Marketing Surveillance Data: Spontaneous adverse event reports submitted through pharmacovigilance systems — including the FDA's FAERS database, the EudraVigilance system in Europe, and India's PvPI ADR Monitoring Centre network — constitute a specialized form of RWD particularly relevant to drug safety applications.

Applications of Real-World Evidence Across the Drug Development Lifecycle

1. Regulatory Decision Support

Regulatory use of RWE has expanded significantly, driven by FDA and EMA frameworks that have created structured pathways for RWE submissions.

New indication approvals: The FDA approved Ibrance (palbociclib) for male breast cancer patients partly on the basis of real-world registry data — a population too small to power a conventional RCT. This case established that RWE could substitute for randomized trial evidence when the target population makes a conventional trial infeasible.

Label expansions: RWE from large observational datasets can demonstrate that an approved drug is used effectively in patient populations outside the approved label — supporting label expansion without requiring a full new trial program.

Post-marketing requirements: Regulators routinely require post-marketing safety studies (PASS) as conditions of approval. Many of these studies use RWD sources rather than conventional trial designs, enabling surveillance at the population scale that makes rare event detection feasible.

Synthetic control arms: In settings where randomized control arms are ethically or practically infeasible — rare diseases, aggressive oncology indications — RWD from historical patient databases can be used to construct synthetic control arms against which single-arm trial results are evaluated. The FDA has increasingly accepted this approach, particularly for rare disease programs.

2. Comparative Effectiveness Research

Comparative effectiveness research (CER) uses RWE to evaluate the relative performance of different treatments as they are actually used in clinical practice. Unlike head-to-head RCTs — which are expensive, slow, and often not conducted — CER using RWD can provide timely evidence on which of several approved therapies performs best in specific patient subgroups, healthcare settings, or geographic populations.

CER findings directly inform clinical guidelines, formulary decisions, and treatment protocols — making RWE a critical input to healthcare policy, not just drug development.

3. Pharmacovigilance and Drug Safety Monitoring

RWE is integral to modern pharmacovigilance infrastructure. The FDA's Sentinel System — a distributed network of electronic health record and claims databases covering over 300 million patient-years of data — actively monitors the safety of approved medical products using real-world data. Sentinel has detected safety signals for multiple products that spontaneous reporting systems alone would have identified far later.

Signal detection using RWD applies validated statistical methods — including self-controlled case series (SCCS), new user active comparator designs, and propensity score-matched cohort analyses — to distinguish true drug safety signals from the confounding background noise inherent in observational data.

In India, the PvPI network's ADR Monitoring Centres generate pharmacovigilance signals that feed into both CDSCO's regulatory decisions and the WHO Uppsala Monitoring Centre's global signal detection program — though the volume and clinical depth of Indian real-world safety data remains an area of active development.

4. Health Economics and Outcomes Research (HEOR)

Payers and health technology assessment (HTA) bodies — including the UK's NICE, Germany's IQWiG, and India's emerging HTA frameworks — increasingly require evidence of cost-effectiveness and real-world health outcomes as conditions for formulary listing and reimbursement. This evidence almost always comes from RWE, since clinical trials are not designed to capture healthcare utilization, cost, or quality-adjusted life year (QALY) endpoints.

RWE-based HEOR studies evaluate healthcare resource utilization, productivity loss, caregiver burden, and treatment patterns in populations that reflect actual payer populations — providing the economic evidence that pricing and access decisions require.

5. Clinical Trial Design and Site Selection

RWE is increasingly used upstream in the development process — to inform RCT design rather than to substitute for it:

• Feasibility assessment: Patient registries and EHR data can estimate the size of the eligible patient population at candidate trial sites before a site is committed to, improving site selection accuracy and enrollment projections.
• Protocol optimization: Real-world data on current treatment patterns, standard of care, and patient adherence helps identify protocol design features that are misaligned with clinical practice — before the protocol is finalized.
• Endpoint selection: PRO data from observational studies can validate that proposed trial endpoints reflect outcomes that matter to patients — a growing regulatory expectation.
• Historical control construction: For early-phase trials and rare disease programs, historical RWD can contextualize single-arm results and support go/no-go decisions.

RWE Study Designs: Matching Method to Question

The credibility of RWE depends fundamentally on study design — specifically, whether the design can adequately control for the confounding that is endemic to observational data. Unlike RCTs, observational studies cannot randomize patients to treatment arms — meaning patients who receive different treatments may differ systematically in ways that affect outcomes, independent of the treatment itself. This is confounding by indication, and it is the central methodological challenge of RWE.

Rigorous RWE study designs address confounding through:

Propensity Score Methods: Statistical techniques that balance treatment and comparison groups on observed baseline characteristics — mimicking the balance achieved by randomization. Propensity score matching, weighting, and stratification are standard tools in observational pharmacoepidemiology.

New User Active Comparator Design: Restricting analysis to patients newly initiating treatment (eliminating prevalent user bias) and comparing to patients initiating an active comparator drug (controlling for confounding by indication that affects the decision to treat). This design substantially improves causal inference in observational settings.

Self-Controlled Case Series (SCCS): Using each patient as their own control by comparing event rates in exposed versus unexposed time periods within the same individual — eliminating confounding by stable patient characteristics.

Instrumental Variable Analysis: Exploiting natural variation in treatment assignment (physician prescribing tendencies, geographic variation in practice) as a quasi-randomization mechanism to estimate causal treatment effects.

Target Trial Emulation: A framework proposed by Miguel Hernán and James Robins at Harvard that explicitly defines the hypothetical RCT that the observational study is intended to emulate — ensuring that observational study design choices are anchored to a clearly specified causal question rather than driven by data availability.

The choice of design depends on the research question, the available data sources, the regulatory context, and the nature of potential confounding. No single method is universally appropriate — and the credibility of an RWE study is evaluated in part by how transparently and rigorously the analytical approach addresses confounding.

Real-World Evidence in India: Opportunities and Challenges

The Opportunity

India's scale, diversity, and evolving digital health infrastructure create genuine opportunities for high-quality RWE generation:

Patient Volume and Disease Burden: India's disease burden across non-communicable diseases — cardiovascular disease, diabetes, oncology, respiratory disease — and infectious diseases creates large patient populations relevant to global development programs. Studies requiring patient populations that are difficult to assemble in Western markets can often be powered from Indian data.

Genetic and Pharmacogenomic Diversity: India's population spans multiple genetic ancestries with distinct pharmacogenomic profiles — affecting drug metabolism, efficacy, and toxicity in ways that Western-derived clinical data cannot characterize. RWE studies in Indian populations can generate evidence with global scientific significance.

Digital Health Infrastructure Growth: India's Ayushman Bharat Digital Mission (ABDM) is building the foundational infrastructure for nationwide electronic health records linkage — including the Health ID system and interoperable digital health records. As ABDM implementation matures, the volume of structured, linkable health data available for research will expand substantially.

Cost Efficiency: RWE studies in India can be conducted at significantly lower cost than equivalent studies in the US or EU — driven by lower data acquisition costs, investigator fees, and operational expenses.

The Challenges

India's RWE landscape faces structural challenges that require honest acknowledgment:

Data Fragmentation and Quality: India's healthcare delivery is highly fragmented across public and private sectors, urban and rural settings, and formal and informal care pathways. EHR adoption remains uneven — many clinical encounters, particularly in primary care and rural settings, are not digitally recorded. The data that does exist is often inconsistently coded, incompletely documented, and difficult to link across episodes of care.

Absence of Standard Coding Systems: Consistent use of structured diagnostic coding (ICD-10), procedure coding, and drug terminology — prerequisites for aggregating and analyzing clinical data at scale — is not yet universal in Indian healthcare settings. Without standardized coding, data from different sources cannot be reliably combined.

Regulatory Framework for RWE: While CDSCO has signaled interest in RWE frameworks appropriate to India, a comprehensive regulatory guidance document equivalent to the FDA's RWE Framework (2019) has not yet been published. Sponsors generating RWE in India for regulatory purposes must navigate this ambiguity carefully.

Data Privacy and Governance: India's Digital Personal Data Protection Act, 2023 (DPDPA) — which came into force in 2023 — establishes a new framework for personal data protection with direct implications for health data research. Research use of patient data requires clear legal basis, appropriate consent or waiver mechanisms, and robust data governance — areas still being operationalized across the Indian research ecosystem.

RWE vs. Clinical Trials: A Framework for Complementarity

RWE and RCTs answer different questions. Understanding which approach is appropriate for which question is more useful than debating which is superior.

Dimension	Randomized Controlled Trial	Real-World Evidence Study
Primary strength	Causal inference, internal validity	Generalizability, external validity
Population	Selected, protocol-defined	Broad, representative of clinical practice
Setting	Controlled, monitored	Routine clinical care
Sample size	Hundreds to thousands	Thousands to millions
Follow-up	Protocol-specified	Can extend indefinitely
Rare event detection	Limited	High capability
Confounding control	Randomization	Statistical and design methods
Cost and time	High, slow	Variable; can be faster and lower cost
Regulatory acceptance	Established	Growing, context-dependent
Best suited for	Efficacy, dose-finding, mechanism	Safety, effectiveness, HEOR, post-market

The most robust evidence base for any medical product combines both — RCT evidence for efficacy and the pre-approval safety profile, RWE for long-term safety, real-world effectiveness, comparative effectiveness, and health economic outcomes.

Regulatory Frameworks Governing RWE

United States: FDA RWE Program

The FDA's RWE Framework (2019) established criteria for evaluating whether RWD is fit for regulatory purposes — assessing data relevance (does it capture the right patients, outcomes, and exposures?) and data reliability (is it complete, accurate, and consistent enough to support valid conclusions?). The FDA has subsequently published specific guidance on RWE for oncology, rare diseases, and medical devices.

European Union: EMA RWE Framework

The EMA's Big Data Taskforce and subsequent initiatives have developed infrastructure for regulatory use of RWE — including the European Health Data Space (EHDS) initiative aimed at creating a federated network of linked health data across EU member states. The EMA now routinely requests RWE as part of regulatory submissions for label expansions and post-marketing commitments.

India: Emerging Framework

CDSCO and India's Health Technology Assessment in India (HTAIn) body have both signaled intent to develop more structured RWE frameworks. The ABDM's digital health infrastructure — if successfully implemented at scale — would provide the data foundation that structured Indian RWE programs require. Sponsors planning RWE activities in India should engage proactively with CDSCO on acceptable data sources, study designs, and regulatory submission formats.

The Role of CROs in RWE Studies

Generating credible RWE requires a distinct skill set from conventional clinical trial operations — one that combines epidemiological methodology, health data science, regulatory strategy, and domain clinical expertise.

An experienced CRO supporting RWE programs contributes:

Study Design and Protocol Development: Selecting the appropriate observational study design for the research question, pre-specifying the statistical analysis plan, and documenting the target trial being emulated — in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) and RECORD (Reporting of studies Conducted using Observational Routinely collected Data) reporting standards.

Data Source Identification and Validation: Identifying RWD sources appropriate to the research question — evaluating data completeness, coding quality, linkage capability, and fitness-for-purpose for the specific study endpoints.

Data Management and Curation: Converting raw RWD into analysis-ready datasets — including data cleaning, variable derivation, missing data handling, and quality documentation that meets regulatory standards.

Biostatistical Analysis: Applying appropriate confounding control methods, conducting sensitivity analyses, and documenting analytical decisions transparently to support regulatory and scientific scrutiny.

Regulatory Submission Support: Preparing RWE study reports in formats acceptable to CDSCO, FDA, EMA, and HTA bodies — and providing scientific justification for the data sources and methods selected.

Conclusion

Real-world evidence has moved from the periphery of clinical research to its mainstream — driven by the convergence of large-scale health data, sophisticated analytical methods, and regulatory frameworks that recognize its scientific value. It does not replace the randomized controlled trial; it extends the evidence base beyond what trials alone can provide.

For sponsors, the strategic question is no longer whether to integrate RWE into development and lifecycle management programs — it is how to do so rigorously, transparently, and in ways that regulatory agencies will accept. That requires the same intellectual standards applied to conventional trials: clear research questions, pre-specified designs, validated data, and honest acknowledgment of limitations.

India, with its patient diversity, growing digital health infrastructure, and cost-competitive research environment, is positioned to become a significant contributor to global RWE generation — if the structural challenges of data quality and regulatory framework development are addressed with appropriate urgency.

Genelife Clinical Research Pvt. Ltd. provides end-to-end RWE study design, data management, and regulatory submission support — combining epidemiological expertise with deep knowledge of India's clinical data landscape. Visit www.genelifecr.com to learn more.

Related Insights

Understand how real-world evidence complements What is Pharmacovigilance  and patient recruitment challenges in clinical trials.

Real World Evidence (RWE) and healthcare market research

Clinical Research services

What is a CRO? Role of Clinical Research Organizations in India